Cancer cells are not able to replicate as fast with forced inhibition of estrogen– known as endocrine therapy – in patients, said Jason Xuan, associate professor at Virginia Tech’s Bradley Department of Electrical and Computer Engineering. This five-year project will focus on creating new computer models to find as yet unknown estrogen receptor-signalling networks to help women with resistance to this medical treatment.
“We will discover new knowledge of estrogen receptor-signalling and ultimately use this information to identify new therapeutic targets for drug discovery,” said Xuan.
About 50 percent of all estrogen receptor-positive tumours are responsive at first presentation to antiestrogens, such as the drug tamoxifen. Yet many initially responsive tumours can become resistant to endocrine treatment, leading to likely tumour recurrence. “If it comes back, then we have no cure anymore,” said Xuan. “We cannot find a drug to battle a recurrence. That’s very troubling.”
We want to take a new look at how breast cancer is treated, but there is so much data and information, without the proper tools it is hard to understand the whole picture, Xuan said. The grant will provide the means to create innovative tools, the engineering feat, to tackle this medical problem.
This computer engineering project is a continuation of a Virginia Tech and Georgetown University Medical Center’s Center for Cancer Systems Biology that focuses on treating breast cancer. Started in 2010, the center seeks to develop more advanced and better targeted treatments for the disease.
Scientists at Virginia Tech already are contributing bioinformatic analysis for the enormous amount of data to be collected by Xuan and his graduate students for the computer modelling.
Xuan hopes that newly developed computational methods will uncover estrogen receptor-signalling networks by integrating protein-protein interaction data and breast cancer gene expression data, thus spurring new research by biomedical engineers. Resulting new discoveries could lead to novel therapies and drugs to overcome endocrine resistance, thus bettering the chances of breast cancer patients against the disease, and cut that deadly 40,000 statistic drastically, Xuan said.
COMPAMED.de; Source: Virginia Tech